SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the first patient has been dosed in a closed loop control ("artificial pancreas") clinical study involving Halozyme's recombinant human hyaluronidase being performed by......
More...